Navigating a New Therapeutic Era for HCC: Expert Review of New Agents and Guideline Recommendations

Chicago, IL US

The goal of this activity is to improve participants’ competence in applying the latest treatment approaches and interdisciplinary collaborative strategies towards optimal care of patients with hepatocellular carcinoma.

Target Audience

This program is designed to meet the educational needs of physicians, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare providers who care for patients with hepatocellular carcinoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explore first-line treatment options for individual patients with advanced HCC, considering the available clinical evidence, known agent toxicity/ tolerability profiles, expert recommendations, and patient preferences.
  • Apply clinical evidence and expert recommendations to select optimal treatment for patients with HCC that has progressed on or after 1 or multiple lines of therapy.
  • Plan therapeutic strategies that optimize the sequence of therapies to provide the best outcome to patients with HCC.
  • Counsel patients to help them understand their treatment options and to be proactive, knowledgeable participants in their care.
  • Employ effective collaborative strategies to ensure the best possible application of the latest HCC treatment approaches.
  • Become familiar with the design of ongoing clinical trials for novel HCC treatment strategies, and counsel appropriate patients about availability and participation.
Additional information
Supporters: 

This activity is supported by an educational grant from:

  • Bayer HealthCare Pharmaceuticals, Inc.
  • Eisai

This educational activity is supported by a medical education grant from Exelixis, Inc.

Course summary
Available credit: 
  • 2.00 AAPA Category 1 CME credit
  • 2.00 ACPE contact hours
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 ANCC contact hours
  • 2.00 Participation
Course opens: 
06/02/2019
Course expires: 
07/28/2019
Cost:
$0.00
Radisson Blu Aqua Hotel
221 N Columbus Drive
Atlantic Ballroom B
Chicago, IL 60601
United States

Thomas A. Abrams, MD
Assistant Professor
Harvard Medical School
Co-Director, Liver Tumor Center
Dana-Farber Cancer Institute
Boston, Massachusetts

R. Kate Kelley, MD
Associate Professor
Division of Hematology and Oncology
University of California, San Francisco
San Francisco, California

Stacey Stein, MD
Assistant Professor of Medicine
Department of Medical Oncology
Yale University
Medical Oncologist
GI Oncology
Yale Cancer Center
New Haven, Connecticut

 

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. National Comprehensive Cancer Network® (NCCN®) and Clinical Care Options, LLC, do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.

The faculty, NCCN staff, and CCO staff reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

Faculty Disclosures

Thomas A. Abrams, MD, has disclosed that he has received consulting fees from Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Ipsen, and Merck and funds for research support from Lilly. 

R. Kate Kelley, MD, has disclosed that she has received consulting fees from Agios, AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech/Roche, and Target PharmaSolutions Bayer and funds for research support (paid to her institution) from Agios, AstraZeneca, Bayer, Bristol-Myers Squibb, Exelixis, Lilly, MedImmune, Merck, Novartis, QED, and Taiho.

Stacey Stein, MD, has disclosed that she has received consulting fees from Bayer, Bristol-Myers Squibb, Eisai, Genentech, and Merck.

Staff Disclosures

The activity planning staff listed below discloses no relevant financial relationships:
CCO: Ryan P. Topping, PhD; Kiran Mir-Hudgeons, PhD; Timothy Quill, PhD; Joy Curzio; Kevin Obholz, PhD
NCCN: Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Karen Kanefield; Kathy Ann Smith, CHCP

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Susan D. Darlow, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 2.0 contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 2.0 contact hours (0.2 CEUs) of continuing education credit. UAN: JA4008196-9999-19-005-L01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 2.00 AAPA Category 1 CME credit
  • 2.00 ACPE contact hours
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 ANCC contact hours
  • 2.00 Participation

Accreditation Period

Course opens: 
06/02/2019
Course expires: 
07/28/2019

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for certificate viewing/printing